COPD Exacerbations Before and During COVID-19 in France, Germany, Italy, the UK and the US.

Publisher: DOVE Medical Press Country of Publication: New Zealand NLM ID: 101273481 Publication Model: eCollection Cited Medium: Internet ISSN: 1178-2005 (Electronic) Linking ISSN: 11769106 NLM ISO Abbreviation: Int J Chron Obstruct Pulmon Dis Subsets: MEDLINE

Original Publication: Auckland, N.Z. : DOVE Medical Press,

COVID-19*/epidemiology ; Pulmonary Disease, Chronic Obstructive*/epidemiology ; Pulmonary Disease, Chronic Obstructive*/diagnosis ; Pulmonary Disease, Chronic Obstructive*/physiopathology ; Disease Progression*; Humans ; Male ; Female ; Aged ; Middle Aged ; SARS-CoV-2 ; United States/epidemiology ; France/epidemiology ; United Kingdom/epidemiology ; Pandemics ; Italy/epidemiology ; Time Factors ; Seasons

Background: Exacerbations of chronic obstructive pulmonary disease (COPD) were reported less frequently during the COVID-19 pandemic. We report real-world data on COPD exacerbation rates before and during this pandemic.
Methods: Exacerbation patterns were analysed using electronic medical records or claims data of patients with COPD before (2017-2019) and during the COVID-19 pandemic (2020 through early 2022) in France, Germany, Italy, the United Kingdom and the United States. Data from each country were analysed separately. The proportions of patients with COPD receiving maintenance treatment were also estimated.
Results: The proportion of patients with exacerbations fell 45-78% across five countries in 2020 versus 2019. Exacerbation rates in most countries were reduced by >50% in 2020 compared with 2019. The proportions of patients with an exacerbation increased in most countries in 2021. Across each country, seasonal exacerbation increases seen during autumn and winter in pre-pandemic years were absent during the first year of the pandemic. The percentage of patients filling COPD prescriptions across each country increased by 4.53-22.13% in 2019 to 9.94-34.17% in 2021.
Conclusion: Early, steep declines in exacerbation rates occurred in 2020 versus 2019 across all five countries and were accompanied by a loss of the seasonal pattern of exacerbation.
Competing Interests: F.J. Martinez reports support for the present manuscript from Chiesi Farmaceutici S.p.A.; reports grants or contracts from AstraZeneca, Chiesi Farmaceutici S.p.A., GSK and Sanofi/Regeneron; reports consulting fees from AstraZeneca, Boehringer Ingelheim, Chiesi Farmaceutici S.p.A., CSL Behring, GSK, Novartis, Polarean, Pulmatrix, Pulmonx, Sanofi/Regeneron, Sunovion, Teva, Theravance/Viatris and UpToDate®; reports payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing or educational events from AstraZeneca and GSK; and reports participation on a Data Safety Monitoring Board or advisory board for GSK and Medtronic. A. Papi reports study support from Chiesi Farmaceutici S.p.A.; reports grants or contracts from Agenzia Italiana del Farmaco (AIFA), AstraZeneca, Chiesi Farmaceutici S.p.A., GSK and Sanofi; reports consulting fees from AstraZeneca, Avillion, Chiesi Farmaceutici S.p.A., Elpen Pharmaceuticals, GSK, Novartis, Roche and Sanofi; reports payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing or educational events from AstraZeneca, Avillion, Chiesi Farmaceutici S.p.A., Edmond Pharma, Elpen Pharmaceuticals, GSK, IQVIA, Menarini, Mundipharma, Novartis, Sanofi and Zambon; and reports advisory board membership for AstraZeneca, Avillion, Chiesi Farmaceutici S.p.A., Elpen Pharmaceuticals, GSK, IQVIA, MSD, Novartis, Regeneron and Sanofi. T. Welte reports all support for the present manuscript from Chiesi Farmaceutici S.p.A.; reports consulting fees from AstraZeneca, Berlin-Chemie, Boehringer Ingelheim, Chiesi Farmaceutici S.p.A. and GSK; and reports payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing or educational events from AstraZeneca, Berlin-Chemie, Boehringer Ingelheim, Chiesi Farmaceutici S.p.A. and GSK. He also reports a grant paid to his institution from the German Ministry of Research and Education. D. Singh reports consulting fees from Aerogen, AstraZeneca, Boehringer Ingelheim, Chiesi Farmaceutici S.p.A., Cipla, CSL Behring, EpiEndo, Genentech, GSK, Glenmark, Gossamer Bio, Kinaset Therapeutics, Menarini, Novartis, Orion, Pulmatrix, Sanofi, Synairgen, Teva, Theravance Biopharma and Verona Pharma. D. Singh is also supported by the National Institute for Health Research Manchester Biomedical Research Centre. D.V. Galkin is an employee of Chiesi Farmaceutici S.p.A.; reports support for this manuscript from Chiesi Farmaceutici S.p.A.; and holds stock or stock options with GSK. A. Guasconi is an employee of Chiesi Farmaceutici S.p.A. S. Pirondi is an employee of Chiesi Farmaceutici S.p.A. and is on SiMEF Società Italiana di Medicina Farmaceutica Working Group on Observational Studies. G. Georges is an employee of Chiesi Farmaceutici S.p.A. J. Imperato and R. Hermans are employees of IQVIA and were on the consulting team that led the analysis of the real-world data for this manuscript. The authors report no other conflicts of interest in this work.
(© 2024 Martinez et al.)

Am J Epidemiol. 2016 Nov 1;184(9):681-689. (PMID: 27737842)
N Engl J Med. 2010 Sep 16;363(12):1128-38. (PMID: 20843247)
EClinicalMedicine. 2021 Mar;33:100789. (PMID: 33758801)
Thorax. 2020 Dec;75(12):1035-1039. (PMID: 32878969)
PLoS One. 2021 Aug 3;16(8):e0255659. (PMID: 34343205)
BMC Med. 2021 May 17;19(1):124. (PMID: 33993870)
J Allergy Clin Immunol Pract. 2020 Jul - Aug;8(7):2384-2385. (PMID: 32371047)
PLoS One. 2016 Mar 09;11(3):e0151357. (PMID: 26959820)
Acta Biomed. 2020 Mar 19;91(1):157-160. (PMID: 32191675)
Air Qual Atmos Health. 2021;14(3):325-332. (PMID: 32952739)
Int J Chron Obstruct Pulmon Dis. 2014 Oct 06;9:1101-10. (PMID: 25336941)
Clin Pharmacol Ther. 2019 Jul;106(1):36-39. (PMID: 30970161)
Ther Adv Respir Dis. 2022 Jan-Dec;16:17534666221081047. (PMID: 35253548)
ERJ Open Res. 2021 Jan 18;7(1):. (PMID: 33527075)
Respir Med. 2022 Jan;191:106120. (PMID: 32839072)
Am J Med. 2021 Oct;134(10):1252-1259.e3. (PMID: 34126098)
BMJ. 2022 Jul 27;378:e069679. (PMID: 35896191)
Int J Chron Obstruct Pulmon Dis. 2018 Feb 14;13:605-616. (PMID: 29497289)
Respir Med. 2020 Sep;171:106085. (PMID: 32917356)
Chronic Obstr Pulm Dis. 2023 Apr 27;10(2):127-138. (PMID: 36599097)
Front Med (Lausanne). 2022 Sep 16;9:995016. (PMID: 36186789)
Eur Respir J. 2017 Mar 15;49(3):. (PMID: 28298398)
Pulm Med. 2021 Jun 23;2021:5533123. (PMID: 34258061)

Keywords: COPD exacerbation; COVID-19; chronic obstructive pulmonary disease; electronic health records; real-world study

Date Created: 20240701 Date Completed: 20240701 Latest Revision: 20240702

20240702

PMC11214557

10.2147/COPD.S451009

38948907